Baden, L. R., Stieh, D. J., Sarnecki, M., Walsh, S. R., Tomaras, G. D., Kublin, J. G., McElrath, M. J., Alter, G., Ferrari, G., Montefiori, D., Mann, P., Nijs, S., Callewaert, K., Goepfert, P., Edupuganti, S., Karita, E., Langedijk, J. P., Wegmann, F., Corey, L., Pau, M. G., Barouch, D. H., Schuitemaker, H., Tomaka, F., , , Ake, J. A., Buchbinder, S., Buleza, K., Cohen, K. W., Crowell, T. A., Euler, Z., Frank, I., Goedhart, D., Keefer, M., Kelly, C., Mayer, K., Nkolola, J., Peter, L., Robb, M. L., Rouphael, N., Scheppler, L., Sobieszczyk, M., & Van Tieu, H. (2020). safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet, 7(10), e688–e698. http://access.bl.uk/ark:/81055/vdc_100110819880.0x000007